Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

•MDR-TB is difficult to manage; updated clinical guidance of new drug use is needed•No recent systematic review/meta-analysis on delamanid (DLM) is available•In observational studies including DLM (591 patients) the success rate was 80.9%•In experimental studies including DLM (391 patients) the succ...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of infectious diseases Ročník 124; číslo Suppl 1; s. S90 - S103
Hlavní autori:	Nasiri, Mohammad Javad, Zangiabadian, Moein, Arabpour, Erfan, Amini, Sirus, Khalili, Farima, Centis, Rosella, D'Ambrosio, Lia, Denholm, Justin T., Schaaf, H. Simon, van den Boom, Martin, Kurhasani, Xhevat, Dalcolmo, Margareth Pretti, Al-Abri, Seif, Chakaya, Jeremiah, Alffenaar, Jan-Willem, Akkerman, Onno, Silva, Denise Rossato, Muňoz-Torrico, Marcela, Seaworth, Barbara, Pontali, Emanuele, Saderi, Laura, Tiberi, Simon, Zumla, Alimuddin, Migliori, Giovanni Battista, Sotgiu, Giovanni
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada Elsevier Ltd 01.11.2022 Elsevier
Predmet:	Antitubercular Agents - therapeutic use bedaquiline delamanid Diarylquinolines - therapeutic use effectiveness Humans MDR-TB Nitroimidazoles - therapeutic use Oxazoles - adverse effects safety Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy effectiveness MDR-TB delamanid bedaquiline safety TB
ISSN:	1201-9712, 1878-3511, 1878-3511
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	•MDR-TB is difficult to manage; updated clinical guidance of new drug use is needed•No recent systematic review/meta-analysis on delamanid (DLM) is available•In observational studies including DLM (591 patients) the success rate was 80.9%•In experimental studies including DLM (391 patients) the success rate was 72.5%•Few adverse events attributable to DLM were reported Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I2: 95.1%) with no evidence of publication bias (Begg's test; P >0.05). In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.
Bibliografia:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	1201-9712 1878-3511 1878-3511
DOI:	10.1016/j.ijid.2022.02.043